Nato allies Germany, Norway vow to step up North Atlantic surveillance
German Chancellor Friedrich Merz (right) and Norwegian Prime Minister Jonas Gahr Store addressing a joint press conference in Berlin on July 21.
BERLIN - Nato allies Germany and Norway agreed on July 21 to step up surveillance against maritime and airborne 'threats' in the northern Atlantic region amid high tensions with Russia over the Ukraine war.
'Germany and Norway aim to ensure stability and security in maritime areas, including in the High North,' said a joint statement released as German Chancellor Friedrich Merz met with Norway's Prime Minister Jonas Gahr Store in Berlin.
The two countries also reaffirmed their 'unwavering support for Ukraine as it defends its freedom, sovereignty, independence and territorial integrity against Russia's continued war of aggression.'
Berlin and Oslo said that 'the North Atlantic, including the strategically crucial Greenland-Iceland-United Kingdom (GIUK) and Bear gaps and adjacent waters, and the North and Baltic Seas, are crucial for both Norwegian and German security.'
This, they said, was why their armed forces trained and patrolled the seas together and 'cooperate closely under Nato's Regional Plans', the statement added.
During the Cold War, Nato kept close watch of the so-called GIUK gap, the key passageway for Soviet submarines and naval vessels from Arctic bases to enter the Atlantic Ocean.
Germany and Norway said they would strengthen their 'surveillance and control over these strategic areas to counter potential threats, including maritime and airborne activities.'
Top stories
Swipe. Select. Stay informed.
Singapore Subsidies and grants for some 20,000 people miscalculated due to processing issue: MOH
Asia At least 19 killed as Bangladesh air force plane crashes at college campus
Singapore ST Explains: What does it mean for etomidate to be listed under the Misuse of Drugs Act?
Business Why Singapore and its businesses stand to lose with US tariffs on the region
Singapore NTU to have compulsory cadaver dissection classes for medical students from 2026
World US authorities probing passenger jet's close call with B-52 bomber over North Dakota
Singapore Jail for man who conspired with another to bribe MOH agency employee with $18k Paris trip
Singapore New research institute will grow S'pore's talent in nuclear energy, safety
They also said that their cooperation in the North Atlantic and North Sea would include 'enhanced protection of critical underwater infrastructure'. AFP
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Straits Times
19 minutes ago
- Straits Times
AstraZeneca unveils $64 billion US investment as as pharma tariff threat looms
Find out what's new on ST website and app. The move by AstraZeneca is the latest by a drugmaker as US President Donald Trump threatens to impose import tariffs on the industry. - AstraZeneca plans to spend US$50 billion (S$64 billion) to expand manufacturing and research capabilities in the United States by 2030, it said on July 21, the latest big investment by a pharmaceutical company reacting to US President Donald Trump's tariff policy. The investment will fund a new drug manufacturing facility in Virginia and expand research and development (R&D) and cell therapy manufacturing in Maryland, Massachusetts, California, Indiana and Texas, it said in a statement. It will also upgrade the Anglo-Swedish drugmaker's US clinical trial supply network and support ongoing investment in novel medicines. AstraZeneca said the expansion supports its ambition to reach US$80 billion in annual revenue by 2030, with half coming from the US. The US accounted for more than 40 per cent of AstraZeneca's annual revenue in 2024, and the company had been prioritising the market – the world's largest, worth US$635 billion – before Mr Trump's return to office. The move to scale up its US footprint is the latest by a drugmaker as Mr Trump threatens to impose import tariffs on the industry and seeks to boost domestic manufacturing. The sector has historically been spared from trade disputes. Mr Trump has called on pharma companies to make more of the medicine they sell in the US within the country, rather than importing active ingredients or finished medicines. He is also pushing for prices in the US to fall to what other countries pay. Top stories Swipe. Select. Stay informed. Singapore Singaporeans aged 21 to 59 can claim $600 SG60 vouchers from July 22 Singapore Miscalculation of MOH subsidies and grants led to $7m in overpayments, $2m in shortfalls Asia Indonesia on high alert as dry weather fans forest, peatland fires in Sumatra Singapore 2 charged over alleged role in posting bail for man who later absconded Singapore Teen charged after allegedly selling vaporisers, advertising e-cigarettes on WhatsApp Singapore Changi Airport handles 17.5 million passengers in Q2 2025 Singapore 2,500 turtles seized in India and sent back to S'pore, put down humanely after salmonella detected Singapore Ports and planes: The 2 Singapore firms helping to keep the world moving AstraZeneca chief executive Pascal Soriot announced the plans in Washington, saying he believes that drug prices need to rise elsewhere and 'equalise', with other countries effectively contributing more to research and development costs. 'The United States cannot build or carry the cost of R&D for the entire world,' he said. US Commerce Secretary Howard Lutnick's department is leading a probe into pharmaceutical imports that could pave the way for new tariffs. 'For decades, Americans have been reliant on foreign supply of key pharmaceutical products. President Trump and our nation's new tariff policies are focused on ending this structural weakness,' said Mr Lutnick in a statement issued by AstraZeneca. While Mr Trump has repeatedly threatened tariffs on the sector, he signalled earlier in July that companies would be given a year to 18 months to 'get their act together' before any levies take effect. The company said that the timing and location of the announcement was linked to the US policy environment, though some of the spending would have occurred regardless so that the infrastructure for future medicines was in place. The pledge is in addition to the US$3.5 billion in investments the company announced in November 2024, the statement said. The US$50 billion pledge matches the commitment announced by Swiss rival Roche in April and follows new spending plans unveiled this year by Eli Lilly & Co, Johnson & Johnson, Novartis, and Sanofi. The new Virginia facility – the company's largest single manufacturing investment – will produce active ingredients for AstraZeneca's experimental weight-loss medicines, including its oral GLP-1 candidate and an oral PCSK9 inhibitor for cholesterol management, it said. Present at the announcement was Virginia State Governor Glenn Youngkin, a vocal Trump ally who has defended the administration's tariff policies. AstraZeneca said its US$50 billion investment could create tens of thousands of new jobs, but declined to give specifics. It employs about 18,000 people in the US and has a global workforce of about 90,000. In January it scrapped plans to invest £450 million (S$777 million) in its vaccine manufacturing plant in northern England, citing a cut in government support. Earlier in July, The Times reported the company was considering moving its stock market listing from London, where it is the exchange's most valuable company, worth £159 billion, to the US. The company declined to comment. REUTERS
Straits Times
an hour ago
- Straits Times
NUS commits $150 million to boost growth of deep tech start-ups via new VC programme
Find out what's new on ST website and app. NUS seeks to enhance support for early stage tech innovation by focusing on high-potential ventures within the university's ecosystem. SINGAPORE - The entrepreneurial arm of the National University of Singapore (NUS) is committing $150 million to a new venture capital (VC) programme, the school said on July 22. Through the NUS Venture Capital Programme, the university will invest $50 million in selected VC firms to support NUS deep tech start-ups. The first two VC partners are Granite Asia, a multi-asset investment platform, and specialist life sciences investor 4Bio Capital, which focuses on advanced therapeutics. The other $100 million will be committed to an autonomous investment fund focused on NUS-affiliated start-ups, which is able to invest alongside selected VC partners. The initiative is the first of its kind in Asia, said NUS, and seeks to enhance support for early stage tech innovation by focusing on high-potential ventures within the university's ecosystem, including start-ups from the National Graduate Research Innovation Programme (Grip). Launched in January, Grip is an incubator programme run by NUS and and Nanyang Technological University to foster start-ups from Singapore's autonomous universities and research institutes. NUS Enterprise's VC programme complements the National Grip framework by addressing the need for downstream venture development. Various National Grip start-ups are still in the early stages of technological readiness and require continued, strategic support to advance from lab to market. While Grip currently provides up to $250,000 in seed funding per start-up, NUS' VC programme focuses on accelerating post-seed growth and preparing ventures for external capital. Top stories Swipe. Select. Stay informed. Singapore Singaporeans aged 21 to 59 can claim $600 SG60 vouchers from July 22 Singapore Miscalculation of MOH subsidies and grants led to $7m in overpayments, $2m in shortfalls Singapore Changi Airport handles 17.5 million passengers in Q2 2025 Singapore 2 charged over alleged role in posting bail for man who later absconded Singapore Teen charged after allegedly selling vaporisers, advertising e-cigarettes on WhatsApp Life Having a workout partner could be the secret to sticking to your fitness goals Singapore 2,500 turtles seized in India and sent back to S'pore, put down humanely after salmonella detected Singapore Ports and planes: The 2 Singapore firms helping to keep the world moving NUS says its VC programme aims to fill funding and mentorship gaps faced by tech start-ups in the region. In 2025, VC investments in Asia-Pacific fell sharply to a 10-year low of $85 billion. With a 5 per cent decline from 2023, early-stage funding has totalled less than $38 billion in 2024. This effort is set apart by direct engagement with leading VC firms selected not only for their track records, but also for their market access in global innovation hubs, said NUS.
Straits Times
an hour ago
- Straits Times
Malaysia's tourist arrivals up 20% from Jan to May, ministry says
Find out what's new on ST website and app. The South-east Asian country recorded just over 25 million international tourist arrivals in 2024, falling short of its 27.3 million target. KUALA LUMPUR - Malaysia recorded 16.9 million international tourist arrivals from January to May of this year, a 20 per cent increase from the same period of 2024, the tourism ministry said. About half of Malaysia's total international tourist arrivals during the first five months of the year were from neighbouring Singapore with 8.34 million visitors, followed by Indonesia at 1.82 million, China at 1.81 million, and Thailand at 1.06 million, the tourism ministry said in a written parliamentary reply on July 21. Arrivals from 'long-haul markets' such as Australia and the United Kingdom also saw increases of 16.6 per cent and 8.7 per cent respectively, compared to the same period in 2024, the ministry added. 'This increase in foreign visitor numbers clearly reflects the effectiveness of various initiatives implemented by the government through strategic approaches, progressive policies such as the visa liberalisation plan, and support and incentives given to industry players,' the ministry said. The South-east Asian country recorded just over 25 million international tourist arrivals in 2024, falling short of its 27.3 million target. Malaysia is targeting 47 million international tourist arrivals in 2026, with a focus on key markets such as Central Asia, the Middle East, Southeast Asia, Europe, and Oceania, the tourism ministry said. REUTERS
